

HETEROCYCLES, Vol. 69, 2006, pp. 49 - 54. © The Japan Institute of Heterocyclic Chemistry
Received, 24th March, 2006, Accepted, 27th April, 2006, Published online, 28th April, 2006. COM-06-S(O)5

TOTAL SYNTHESIS OF (-)-PRAMANICIN[‡]

**Shin-ya Aoki, Taro Tsukude, Yukari Miyazaki, Ken-ichi Takao, and
Kin-ichi Tadano***

Department of Applied Chemistry, Keio University, Hiyoshi, Kohoku-ku,
Yokohama 223-8522, Japan
tadano@applc.keio.ac.jp

Abstract – The total synthesis of natural (-)-pramanicin, a highly oxygenated γ -lactam-type antifungal agent, is described. The enantiospecific total synthesis of this natural product commenced with 5-deoxy-1,2-*O*-isopropylidene- α -D-xylofuranose as an enantiopure starting material.

(-)-Pramanicin (-)-**1** (Figure 1), isolated from the fungus *Stagonospora* species by Schwartz and coworkers in 1994,¹ showed moderate antifungal activity against various fungal strains, including *Candida* sp. and *Cryptococcus neoformans*, as well as antibacterial activity against *Bacillus subtilis*. Later, Kwan and coworkers reported that (-)-**1** has a cytotoxic effect on vascular endothelial cells, resulting in the loss of vasorelaxant function.² Recently, Basaga and coworkers reported that (-)-**1** induces apoptosis in Jurkat leukemia cells.³ The structure of (-)-**1**, including its relative stereochemistry, was determined by a combination of 1-D and 2-D NMR techniques, mass spectral analysis, and chemical modification.¹ Harrison and coworkers explored the incorporation experiment of labeled acetates and serine into (-)-**1**, which reveals that the carbon framework of (-)-**1** is derived from eight acetate and a serine residue.⁴ Through a biosynthetic experiment, the absolute configuration of (-)-**1** was determined. Furthermore, Barrett and coworkers reported the total synthesis of the antipode (+)-**1**, establishing the absolute stereochemistry of pramanicin.⁵ The structurally related natural product TMC-260 (**2**) was isolated in 2003 from the fermentation broth of *Acremonium kiliense* Grüetz TC 1703 as an inhibitor of





Figure 1. Structures of (-)-pramanicin (-)-**1** and TMC-260 **2**

[‡] This paper is dedicated to Dr. Satoshi Omura (The Kitasato Institute, and Kitasato Institute of Life Science, Kitasato University) with respect and admiration on the occasion of his 70th birthday.

interleukin-4 signal transduction.⁶ These two natural products (–)-(1) and (2) consist of a highly oxygenated and γ -alkylated γ -lactam with a lipophilic side chain containing a γ,δ -epoxyenone structure. We describe herein the total synthesis of natural (–)-pramanicin (–)-(1) using a carbohydrate derivative as a chiron.⁷

Our total synthesis began with the known 5-deoxy-1,2-*O*-isopropylidene- α -D-xylofuranose (**3**), prepared conveniently from D-xylose.⁸ Oxidation of **3** with PCC, followed by a vinyl Grignard addition to the 3-uloose (**4**), provided the desired β -oriented adduct (**5**) as a single diastereomer (Scheme 1).⁹ The vinyl nucleophile exclusively attacked the convex face of the trioxabicyclo[3.3.0]octane structure of **4**. Acidic hydrolysis of the acetal moiety in **5** and subsequent chemoselective oxidation of the hemiacetal hydroxyl group with *N*-iodosuccinimide (NIS) provided γ -lactone- α,β -diol (**6**). The diol in **6** was protected as the isopropylidene acetal affording **7**, which was reduced with LiAlH₄ to provide an acyclic 1,4-diol (**8**). A three-step protection/deprotection sequence from **8** via the primary trityl ether provided the secondary benzyl ether (**9**). Dess–Martin oxidation¹⁰ of **9** produced a five-carbon aldehyde (**10**).




Reagents and conditions: a) PCC, MS4A, CH₂Cl₂; b) CH₂=CHMgBr, THF, –18 °C, 73% for 2 steps; c) 80% aq. AcOH, 80 °C; d) NIS, *n*-Bu₄NI, CH₂Cl₂, 77% for 2 steps; e) Me₂C(OMe)₂, acetone, CSA, reduced pressure (ca. 300 hPa), 40 °C, 72%; f) LiAlH₄, THF, 0 °C, 94%; g) TrCl, DMAP, pyr, reflux; h) BnBr, NaH, DMF; i) CSA, MeOH, 89% for 3 steps; j) Dess–Martin periodinane, CH₂Cl₂, 99%.

Scheme 1

The addition of the 2-lithiated 1,3-dithiane, prepared from 1,3-dithiane (**11**) and *n*-BuLi (excess) in THF at –18 °C, to **10** produced the 1,3-dithiane (**12**) as a single stereoisomer in an excellent yield of 97% (Scheme 2). The configuration of the newly introduced stereogenic center in **12** shown as depicted was established later. This exclusive stereoselective addition of the 2-lithiated 1,3-dithiane to **10** can be explained using a depicted lithium-ion-associated five-member chelation-controlled transition state, in which the nucleophile attacks from the less hindered β -side leading to **12**. Protection of the secondary hydroxyl group in **12** as a methoxymethyl (MOM) ether and subsequent conversion of the 1,3-dithiane moiety in the MOM ether (**13**) into the primary hydroxyl group was achieved with methyl iodide in wet

CH₃CN at 50 °C, followed by treatment with NaBH₄ in the presence of CeCl₃·7H₂O in a mixed solvent of DMPU and cyclohexene (1:1, v/v), providing **14**. Protection of the hydroxyl group in **14** as a benzyl ether afforded **15**.¹¹ Ozonolysis of the carbon–carbon double bond in **15**, followed by simultaneous hydrolysis of the isopropylidene acetal and the MOM group, provided γ -lactol (**16**). The lactol carbon in **16** was oxidized with NIS to provide γ -lactone- α,β -diol (**17**). The two hydroxyl groups in **17** were protected as *O*-MOM ethers to provide fully protected γ -lactone (**18**). Treatment of **18** with liquid NH₃ (sealed tube) at room temperature provided a ring-opened amidation product quantitatively, which was subjected to chemoselective *O*-mesylation to provide the *O*-mesylate (**19**).




Reagents and conditions: a) **11** (6.0 equiv), *n*-BuLi (6.0 equiv), THF, -18 °C, then **10**, 97%; b) MOMCl, *i*-Pr₂NEt, CH₂Cl₂ reflux, 96%; c) MeI, CH₃CN/H₂O (4:1, v/v), 50 °C; d) NaBH₄, CeCl₃·7H₂O, DMPU/cyclohexene (1:1, v/v), 0 °C; e) BnBr, NaH, DMF, 0 °C, 86% for 3 steps; f) O₃, CH₂Cl₂, -78 °C; Ph₃P; g) 60% aqueous CF₃CO₂H; h) NIS, *n*-Bu₄NI, CH₂Cl₂, 92% for 3 steps; i) P₂O₅, CH₂(OMe)₂, CHCl₃, 0 °C, 79%; j) *i*-PrOH/liquid NH₃ (1:1, v/v) in a sealed tube; k) MsCl, Et₃N, 1,2-dimethoxyethane, -18 °C, 83% for 2 steps.

Scheme 2

The desired γ -lactamization via S_N2-displacement of the mesyloxy group by the amide anion generated from **19** was then explored (Scheme 3). Treatment of the mesylate (**19**) with NaH (3.0 molar equiv) in DMSO at room temperature and subsequent acidic cleavage of the MOM ethers provided two cyclization products, i.e., the desired γ -lactam (**20**)¹² (52%) and the γ -lactone (**21**)¹³ (44%). In this S_N2-type cyclization step, the attack of the amide anion (N⁻) (desired) and that of the imidate anion (O⁻) (undesired)

competed. We examined other basic conditions for the attempted γ -lactamization, however, the yield of **20** could not be improved.¹⁴ The liberated hydroxyl groups in **20** were protected as TES ethers to provide **22**. Deprotection of the benzyl groups in **22** by hydrogenolysis, followed by regioselective *O*-silylation, provided a tri-*O*-triethylsilyl (TES) derivative (**23**). The remaining hydroxyl group in **23** was oxidized to produce methyl ketone (**24**). On the other hand, enantiomeric (2*S*,3*R*)-2,3-epoxydodecanal (**25**) (>99% ee, HPLC analysis) as the side-chain precursor was synthesized from *n*-decylaldehyde according to the reported procedure.⁵ The attempted aldol reaction of **24** and **25** was best achieved as follows. Deprotonation of **24** with KHMDS (2.0 molar equiv) in THF at -78 °C, followed by the addition of **25** (3.0 molar equiv), provided the desired aldol adducts as a 3:2 diastereomeric mixture (¹H NMR analysis). Acetylation of the aldol mixture, followed by treatment with hot pyridine, afforded the γ,δ -epoxyenone (**26**) in 43% yield from **24**. Removal of the *O*-TES groups in **26** completed the total synthesis of (–)-pramanicin (–)-(**1**). The spectroscopic data (mp, IR, ¹H and ¹³C NMR, HRMS) and optical property of synthetic (–)-**1** matched well those reported for natural (–)-**1** in all respects.¹⁵ In summary, we have accomplished the total synthesis of natural (–)-pramanicin (–)-(**1**) for the first time by using a carbohydrate-based chiron approach.



Reagents and conditions: a) NaH, DMSO; b) 8 M HCl/MeOH (1:1, v/v), 52% for **20** and 44% for **21** for 2 steps; c) TESOTf, pyr, 40 °C, 95%; d) H₂, 10% Pd on C, EtOAc; e) TESCl, pyr, CH₂Cl₂, -18 °C, 93% for 2 steps; f) Dess–Martin periodinane, CH₂Cl₂, 91%; g) KHMDS, THF, -78 °C then **25**; h) Ac₂O, pyr; i) pyr, 90 °C, 43% for 3 steps; j) HF·pyridine complex, pyr, 88%.

Scheme 3

REFERENCES AND NOTES

1. R. E. Schwartz, G. L. Helms, E. A. Bolessa, K. E. Wilson, R. A. Giacobbe, J. S. Tkacz, G. F. Bills, J. M. Liesch, D. L. Zink, J. E. Curotto, B. Pramanik, and J. C. Onishi, *Tetrahedron*, 1994, **50**, 1675.
2. C.-Y. Kwan, P. H. M. Harrison, P. A. Duspara, and E. E. Daniel, *Jpn. J. Pharmacol.*, 2001, **85**, 234.
3. O. Kutuk, A. Pedrech, P. Harrison, and H. Basaga, *Apoptosis*, 2005, **10**, 597.

4. P. H. M. Harrison, P. A. Duspara, S. I. Jenkins, S. A. Kassam, D. K. Liscombe, and D. W. Hughes, *J. Chem. Soc., Perkin Trans. 1*, **2000**, 4390, and references therein.
5. A. G. M. Barrett, J. Head, M. L. Smith, N. S. Stock, A. J. P. White, and D. J. Williams, *J. Org. Chem.*, **1999**, **64**, 6005.
6. M. Sakurai, H. Hoshino, J. Kohno, M. Nishino, N. Kishi, T. Okuda, K. Kawano, and T. Ohnuki, *J. Antibiot.*, **2003**, **56**, 787.
7. We have achieved total syntheses of some highly oxygenated γ -lactam-type natural products starting from D-glucose. For pseurotins A, F₂, and azaspirene, see: (a) S. Aoki, T. Oi, K. Shimizu, R. Shiraki, K. Takao, and K. Tadano, *Bull. Chem. Soc. Jpn.*, **2004**, **77**, 1703. (b) S. Aoki, T. Oi, K. Shimizu, R. Shiraki, K. Takao, and K. Tadano, *Heterocycles*, **2004**, **62**, 161. (c) S. Aoki, T. Ohi, K. Shimizu, R. Shiraki, K. Takao, and K. Tadano, *Heterocycles*, **2002**, **58**, 57. For PI-091, see: (d) R. Shiraki and K. Tadano, *Rev. Heteroatom Chem.*, **1999**, **20**, 283. (e) R. Shiraki, A. Sumino, K. Tadano, and S. Ogawa, *J. Org. Chem.*, **1996**, **61**, 2845. (f) R. Shiraki, A. Sumino, K. Tadano, and S. Ogawa, *Tetrahedron Lett.*, **1995**, **36**, 5551.
8. B. Hildebrandt, Y. Nakamura, and S. Ogawa, *Carbohydr. Res.*, **1991**, **214**, 87.
9. All new compounds were fully characterized by spectroscopic means [¹H NMR (300 MHz in CDCl₃ or CD₃OD) and ¹³C NMR (75 MHz in CDCl₃ or CD₃OD), IR] and gave satisfactory HRMS spectrum. Yields referred to homogeneous samples purified by chromatography on silica gel.
10. (a) D. B. Dess and J. C. Martin, *J. Org. Chem.*, **1983**, **48**, 4155. (b) D. B. Dess and J. C. Martin, *J. Am. Chem. Soc.*, **1991**, **113**, 7277. (c) R. E. Ireland and L. Liu, *J. Org. Chem.*, **1993**, **58**, 2899.
11. Compound (**15**) was converted into known (2*S*)-2,3-bis(benzyloxy)propanol (1,2-di-*O*-benzyl-*sn*-glycerol) by the following reaction sequence: 1) cleavage of the MOM group (CSA/MeOH, 76%); 2) benzylation of the resulting hydroxyl group (BnBr/NaH/DMF, 74%); 3) hydrolysis of the isopropylidene acetal (80% aqueous AcOH/60 °C, 94%); 4) oxidative cleavage of the resulting diol (NaIO₄/MeOH–H₂O); and 5) reduction of the resulting aldehyde (NaBH₄/MeOH, 81% for 2 steps). Comparison of the optical properties between the synthetic sample {[α]_D²³ –17.0 (c 0.23, CHCl₃)} and the reported one for (2*S*)-2,3-bis(benzyloxy)propanol {[α]_D²¹ –17.2 (c 1, CHCl₃)} [C. A. A. van Boeckel, G. M. Visser, and J. H. van Boom, *Tetrahedron*, **1985**, **41**, 4557] concluded the (*S*)-configuration for the newly introduced stereogenic center in **12**.
12. Compound (**20**) was obtained as colorless crystals: mp 152.0–152.4 °C; TLC R_f 0.35 (EtOAc/hexane, 1:1); [α]_D²³ –39.5 (c 0.500, CHCl₃); IR (neat) 3400, 2920, 1695 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.42 (d, 3H, *J* = 6.4 Hz), 2.91 (d, 1H, *J* = 7.1 Hz), 3.01 (br s, 1H), 3.35 (dd, 1H, *J* = 8.3, 9.4 Hz), 3.66 (ddd, 1H, *J* = 3.2, 7.1, 8.3 Hz), 3.74 (dd, 1H, *J* = 3.2, 9.4 Hz), 4.00 (q, 1H, *J* = 6.4 Hz), 4.06 (t, 1H, *J* = 7.1 Hz), 4.51 (s, 2H), 4.52, 4.70 (AB q, each 1H, *J* = 11.5 Hz), 5.93 (br s, 1H), 7.27–7.43 (m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 13.5, 58.4, 71.4, 71.7, 73.5, 78.9, 79.2 \times 2, 127.8 \times 3, 128.0 \times 3, 128.1

- × 2, 128.6 × 2, 137.3, 137.5, 173.9; HRMS calcd for C₂₁H₂₅NO₅ (M⁺) *m/z* 371.1733, found 371.1732.
13. Compound (**21**) was obtained as colorless crystals: mp 89.7–90.8 °C; TLC *R_f* 0.44 (EtOAc/hexane, 1:1); [α]_D²⁴ +30.3 (*c* 1.60, CHCl₃); IR (neat) 3450, 2920, 1790 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.43 (d, 3H, *J* = 6.4 Hz), 2.80 (d, 1H, *J* = 5.8 Hz), 3.21 (s, 1H), 3.68, 3.74 (2 dd, each 1H, *J* = 3.2, 11.5 Hz), 4.11 (q, 1H, *J* = 6.4 Hz), 4.40 (dt, 1H, *J* = 6.4, 3.2 Hz), 4.42 (dd, 1H, *J* = 5.8, 6.4 Hz), 4.52, 4.71 (AB q, each 1H, *J* = 11.3 Hz), 4.55, 4.61 (AB q, each 1H, *J* = 12.0 Hz), 7.26–7.40 (m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 13.2, 68.3, 71.2, 73.6, 75.4, 76.7, 78.6, 81.6, 127.8 × 3, 127.90 × 2, 127.94 × 2, 128.5 × 3, 137.2, 137.4, 175.4; HRMS calcd for C₂₁H₂₄O₆ (M⁺) *m/z* 372.1573, found 372.1581.
14. We examined the following reaction conditions: a) NaH, DMF, 0 °C (36% for **20**, 52% for **21**); b) NaH, DMPU (**20**: 33%, **21**: 53%); c) NaH, benzene (**20**: 35%, **21**: 42%). Under the following reaction conditions, the γ-lactone (**21**) was a sole product: a) saturated aqueous Na₂CO₃, 1,2-dichloroethane, 60 °C (87%); b) LiH, DMF, 50 °C (94%); c) Cs₂CO₃, MeOH (94%).
15. (–)-Pramanicin (–)-(**1**) was obtained as colorless crystals: mp 118.6–120.5 °C; TLC *R_f* 0.13 (EtOAc); [α]_D²⁴ –34.0 (*c* 0.150, CH₃OH) {[α]_D²⁵ –35 (*c* 0.21, CH₃OH)¹ for natural (–)-**1**; [α]_D²⁵ +28.8 (*c* 0.21, CH₃OH)⁵ for synthetic (+)-**1**}; IR (KBr) 3360, 2940, 1715, 1690, 1635 cm⁻¹; ¹H NMR (300 MHz, CD₃OD) δ 0.89 (t, 3H, *J* = 6.6 Hz), 1.29 (br s, 12H), 1.46 (m, 2H), 1.60 (m, 2H), 2.93 (ddd, 1H, *J* = 2.0, 5.1, 6.1 Hz), 3.31 (m, 1H), 3.47 (ddd, 1H, *J* = 2.7, 5.4, 7.1 Hz), 3.54 (dd, 1H, *J* = 5.4, 11.5 Hz), 3.79 (dd, 1H, *J* = 2.7, 11.5 Hz), 4.15 (d, 1H, *J* = 7.1 Hz), 6.64 (dd, 1H, *J* = 7.1, 15.6 Hz), 7.05 (dd, 1H, *J* = 0.7, 15.6 Hz); ¹³C NMR (75 MHz, CD₃OD) δ 14.4, 23.7, 27.0, 30.45, 30.51, 30.56, 30.64, 33.1 × 2, 57.8, 60.3, 62.0, 62.9, 78.9, 88.1, 127.9, 145.1, 175.0, 197.9; HRMS calcd for C₁₉H₃₁NO₆ (M⁺) *m/z* 369.2151, found 369.2149.